Kinnate Biopharma Inc reports results for the quarter ended in December - Earnings Summary

Reuters03-30

* Kinnate Biopharma Inc reported a quarterly adjusted loss of 36 cents​​ per share for the quarter ended in December, higher than the same quarter last year, when the company reported EPS of -72 cents. The mean expectation of six analysts for the quarter was for a loss of 42 cents per share. Wall Street expected results to range from -50 cents to -37 cents per share.

* Reported revenue was zero​; analysts expected zero.

* Kinnate Biopharma Inc's reported EPS for the quarter was a loss of 36 cents​.

* The company reported a quarterly loss of $17.06 million.

* Kinnate Biopharma Inc shares had risen by 12.2% this quarter.

FORECAST CHANGES

* The mean earnings estimate of analysts was unchanged in the last three months.​

* In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy," 3 "hold" and no "sell" or "strong sell."

* Wall Street's median 12-month price target for Kinnate Biopharma Inc is $2.50

This summary was machine generated from LSEG data March 29 at 07:05 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,

MISSED

Dec. 31 2023 -0.42 -0.36 Beat

Sep. 30 2023 -0.67 -0.65 Beat

Jun. 30 2023 -0.75 -0.68 Beat

Mar. 31 2023 -0.73 -0.73 Met

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment